2023. Lebrikizumab Demonstrates Consistent Efficacy at 16 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis Regardless of Baseline Disease Severity. SKIN The Journal of Cutaneous Medicine. 7, 6 (Nov. 2023), s274. DOI:https://doi.org/10.25251/skin.7.supp.274.